Table 4.
Association between the HCC-SurvNet risk score and various patient characteristics in the external test (Stanford-HCC) cohort.
| Patient characteristics | Stanford-HCC (n = 198) | Spearman’s correlation | ||
|---|---|---|---|---|
| Low-risk group (N = 166) | High-risk group (N = 32) | ρ (95% CI) | p value | |
| Age (at surgery) | 64 (57, 69) | 64 (57, 69) | − 0.017 (− 0.15, 0.12) | 0.82 |
| Gender | 0.036 (− 0.11, 0.18) | 0.62 | ||
| Male | 133 (80%) | 24 (75%) | ||
| Female | 33 (20%) | 8 (25%) | ||
| Hepatitis B virus infection | − 0.033 (− 0.17, 0.10) | 0.64 | ||
| Negative | 121 (73%) | 26 (81%) | ||
| Positive | 45 (27%) | 6 (19%) | ||
| Hepatitis C virus infection | − 0.082 (− 0.22, 0.063) | 0.25 | ||
| Negative | 80 (48%) | 16 (50%) | ||
| Positive | 86 (52%) | 16 (50%) | ||
| Alcohol intake | − 0.024 (− 0.18, 0.13) | 0.74 | ||
| Negative | 152 (92%) | 29 (91%) | ||
| Positive | 14 (8.4%) | 3 (9.4%) | ||
| Non-alcoholic fatty liver disease | − 0.0014 (− 0.10, 0.092) | 0.99 | ||
| Negative | 152 (92%) | 32 (100%) | ||
| Positive | 14 (8.4%) | 0 (0%) | ||
| AJCC stage grouping | 0.24 (0.086, 0.37) | 0.00079 | ||
| IA | 43 (26%) | 1 (3.1%) | ||
| IB | 53 (32%) | 13 (41%) | ||
| II | 57 (34%) | 11 (34%) | ||
| IIIA | 7 (4.2%) | 4 (12%) | ||
| IIIB | 5 (3.0%) | 2 (6.2%) | ||
| IVA | 1 (0.6%) | 1 (3.1%) | ||
| IVB | 0 (0%) | 0 (0%) | ||
| Largest tumor diameter (mm) | 26 (15, 45) | 55 (36, 80) | 0.41 (0.27, 0.53) | < 0.0001 |
| Tumor multifocality | − 0.10 (− 0.24, 0.032) | 0.15 | ||
| Negative | 188 (71%) | 24 (75%) | ||
| Positive | 48 (29%) | 8 (25%) | ||
| Histologic grade | 0.14 (− 0.0046, 0.27) | 0.058 | ||
| Well-differentiated | 57 (34%) | 6 (19%) | ||
| Moderately-differentiated | 89 (54%) | 19 (59%) | ||
| Poorly-differentiated | 19 (11%) | 7 (22%) | ||
| Undifferentiated | 1 (0.6%) | 0 (0%) | ||
| Microvascular invasion | 0.22 (0.082, 0.35) | 0.0015 | ||
| Negative | 128 (77%) | 19 (59%) | ||
| Positive | 38 (23%) | 13 (41%) | ||
| Macrovascular invasion | 0.056 (− 0.13, 0.23) | 0.44 | ||
| Negative | 159 (97%) | 29 (91%) | ||
| Positive | 5 (3.0%) | 3 (9.4%) | ||
| Surgical margin status | 0.060 (− 0.079, 0.18) | 0.40 | ||
| Negative | 159 (97%) | 29 (91%) | ||
| Positive | 5 (3.0%) | 3 (9.4%) | ||
| Unknown | 2 | 0 | ||
| Fibrosis stage | − 0.36 (− 0.48, − 0.22) | < 0.0001 | ||
| 0 | 29 (17%) | 9 (28%) | ||
| 1 | 8 (4.8%) | 5 (16%) | ||
| 2 | 12 (7.2%) | 3 (9.4%) | ||
| 3 | 9 (5.4%) | 4 (12%) | ||
| 4 | 108 (65%) | 11 (34%) | ||
Values presented: median (IQR); n (%).